Genetron Health Announces Pricing of Initial Public Offering

Genetron Health Announces Pricing of Initial Public Offering

IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19

Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19

Legend Biotech Corporation Announces Pricing of Initial Public Offering

Legend Biotech Corporation Announces Pricing of Initial Public Offering

RemeGen Completes USD $100 Million Plus in Funding

RemeGen Completes USD $100 Million Plus in Funding

Gilead to Acquire Forty Seven for $4.9 Billion

Gilead to Acquire Forty Seven for $4.9 Billion

Passage Bio Announces Pricing of Initial Public Offering

Passage Bio Announces Pricing of Initial Public Offering

Revolution Medicines Announces Pricing of Initial Public Offering

Revolution Medicines Announces Pricing of Initial Public Offering

Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors

Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

IGM Biosciences Announces Pricing of Initial Public Offering

IGM Biosciences Announces Pricing of Initial Public Offering

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis

Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis

Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine

Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine

Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering

Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering

Tricida Announces Pricing of Initial Public Offering

Tricida Announces Pricing of Initial Public Offering